← 프로그램 목록
Phase 3Recruiting

Zanubrutinib

Juan P. AlderuccioMD

비교

Zanubrutinib(Juan P. Alderuccio, MD)은 CNS Lymphoma 표적 치료제로, CNS Lymphoma 영역에서 개발·상용화 중입니다. 작용기전: inhibits B-cell receptor signaling. Phase 3 후기 임상 단계입니다. 대표 임상 효능: ORR 95.2% (ClinicalTrials.gov NCT02343120). 차별점: novel agents.

출처: ClinicalTrials.gov · PubMed · openFDA최근 동기화됨

개요

임상 2026년 7월 8일 (6일 전)PK/독성 2026년 7월 8일 (6일 전)

CNS Lymphoma

CNS Lymphoma

Recruiting

Technology

구조모아 · MMAE (auristatin)

CAR T) therapy has shown promise in treating B-cell non-Hodgkin l

vedotin efficacy in DLBCL with concurrent CD79b

retroviral-BTK Inhibitor Interactions and Provide Recommendations for Co-Administration Re

novel agents

Mechanism of Action

inhibits B-cell receptor signaling

immune-mediated thrombocytopenias (IMTs) in which anti-platelet factor 4 (PF4) antibodies activate platelets independently of heparin,

apoptosis induced by venetoclax and AZD5991

biomarker to guide treatment duration in two prospective trials of venetoclax- and sonrotoclax-based triplets

resistance to ncBTKi can occur owing to second site aberrations in BTK, generating novel mutations such as L528x and T316x

임상시험 & 결과

차트 로드 중…

임상 한눈에 보기

  • 80건의 ClinicalTrials.gov 임상 기록
  • Phase·Status 요약은 enrollment 상위 표본 기준입니다
  • 임상시험 탭에서 enrollment 상위 목록을 불러올 수 있습니다
  • Phase: Phase 3 · Phase 1, Phase 2
  • Status: Not yet recruiting · Recruiting · Active, not recruiting
  • 주요 endpoint: Risk of incident atrial fibrillation in patients exposed to zanubrutinib compared with those exposed to acalabrutinib in the matched cohort. · Risk of all-cause mortality in patients exposed to zanubrutinib compared with those exposed to acalabrutinib in thematched cohort · Risk of incident intra-cerebral hemorrhage in patients exposed to zanubrutinib compared with those exposed to acalabrutinib in the matched cohort · Risk of incident major bleeding in patients exposed to zanubrutinib compared with those exposed to acalabrutinib in the matched cohort · Risk of incident hypertension in patients exposed to zanubrutinib compared with those exposed to acalabrutinib in the matched cohort
  • 등록된 결과: ORR 95.2%
  • PFS: 61.4
  • 핵심: This study evaluated the safety, tolerability, pharmacokinetic profile and efficacy of BGB-3111 in participants with B-c…

임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.

수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.

참고문헌

자주 묻는 질문

Zanubrutinib은 어떤 치료제인가요?
Zanubrutinib(Juan P. Alderuccio, MD)은 CNS Lymphoma 표적 항체로, CNS Lymphoma 영역에서 개발·상용화 중입니다. 데이터는 바이오모아 (BioMoa)에서 ClinicalTrials.gov·openFDA·PubMed 기반으로 정리합니다.
Zanubrutinib의 임상 단계는?
Zanubrutinib의 현재 단계는 Phase 3입니다.
비슷한 프로그램과 어떻게 비교하나요?
바이오모아 (BioMoa) 비교 페이지에서 PK/PD, 독성, 임상 효능 지표를 나란히 볼 수 있습니다. 동일 타깃·모달리티 프리셋을 함께 참고하세요.